US20230324403A1 - One-step fast gradient method for nanoantibody generation - Google Patents
One-step fast gradient method for nanoantibody generation Download PDFInfo
- Publication number
- US20230324403A1 US20230324403A1 US17/998,753 US202117998753A US2023324403A1 US 20230324403 A1 US20230324403 A1 US 20230324403A1 US 202117998753 A US202117998753 A US 202117998753A US 2023324403 A1 US2023324403 A1 US 2023324403A1
- Authority
- US
- United States
- Prior art keywords
- beads
- antigen
- nanoantibodies
- hhv
- microorganisms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 41
- 239000000427 antigen Substances 0.000 claims abstract description 46
- 108091007433 antigens Proteins 0.000 claims abstract description 46
- 102000036639 antigens Human genes 0.000 claims abstract description 46
- 239000011324 bead Substances 0.000 claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 39
- 230000014509 gene expression Effects 0.000 claims abstract description 22
- 244000005700 microbiome Species 0.000 claims abstract description 19
- 230000027455 binding Effects 0.000 claims abstract description 15
- 238000000926 separation method Methods 0.000 claims abstract description 8
- 229920000642 polymer Polymers 0.000 claims abstract description 3
- 239000006228 supernatant Substances 0.000 claims abstract description 3
- 239000002609 medium Substances 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 229920002684 Sepharose Polymers 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 239000011049 pearl Substances 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 36
- 241001416177 Vicugna pacos Species 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 24
- 238000002649 immunization Methods 0.000 description 22
- 230000003053 immunization Effects 0.000 description 22
- 102000044159 Ubiquitin Human genes 0.000 description 15
- 108090000848 Ubiquitin Proteins 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229960005091 chloramphenicol Drugs 0.000 description 9
- 229920001917 Ficoll Polymers 0.000 description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 8
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 108010068086 Polyubiquitin Proteins 0.000 description 7
- 102100037935 Polyubiquitin-C Human genes 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 229940096437 Protein S Drugs 0.000 description 6
- 101710198474 Spike protein Proteins 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 101100239628 Danio rerio myca gene Proteins 0.000 description 5
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 5
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 241000282832 Camelidae Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical group CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000010798 ubiquitination Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 235000002198 Annona diversifolia Nutrition 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 101710167241 Intimin Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- 230000034512 ubiquitination Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108700012439 CA9 Proteins 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 241000282838 Lama Species 0.000 description 2
- 241000282852 Lama guanicoe Species 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 241000282840 Vicugna vicugna Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000017730 intein-mediated protein splicing Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 238000012831 peritoneal equilibrium test Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000012636 positron electron tomography Methods 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 229940124931 vaccine adjuvant Drugs 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241001416183 Ginglymostomatidae Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000251471 Hydrolagus colliei Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000881705 Porcine endogenous retrovirus Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000009504 deubiquitination Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 108700002314 gontivimab Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Definitions
- the invention relates to a new one-step fast gradient method for the rapid separation of nanoantibodies against any antigen.
- HCAb single-domain antibodies
- the Camelidae or camelid family is composed of camels, dromedaries, llamas, vicu ⁇ as, guanacos and alpacas.
- the antigen-binding fragment of an HCAb contains a single variable HHV domain consisting of 3 hypervariable regions (RDA). When isolated, the HHV domain is also known as a nanoantibody.
- Target-specific nanoantibodies derived from camelid HCAbs are obtained after immunization with the antigen, plus the adjuvant. Our platform has developed an improved procedure for obtaining nanoantibodies by using alpacas as a donor species.
- RNA RNA
- cDNA preparation to finally amplify the nanoantibody region.
- the cDNA fragment encoding the nanoantibody is as short as 360 nt, and up to ⁇ 3 ⁇ 10 6 individual clones can be obtained from 120 ml of blood from an immunized alpaca.
- a bacteria or yeast visualization system is used to clone the various complete individual nanoantibodies, generating what is known as a nanoantibody or HHV library.
- Microorganism presentation technology allows nanoantibodies to be expressed on the surfaces of microorganisms and therefore researchers can separate and enrich bacteria or yeasts expressing the nanoantibody of interest on their surface by means of affinity purification. Final isolated nanoantibodies are expressed recombinantly in bacteria and their binding capabilities can be characterized by ELISA and quantitative biochemical parameters such as ITC. In addition to targeted immunization, it is also possible to use very large libraries of nanoantibodies (1 ⁇ 10 9 ) to find binding nanoantibodies using a stochastic approach. The nanoantibodies are then produced in a renewable and economical manner.
- single-domain antibodies HCAb
- HCAb single-domain antibodies
- the Camilidae or camelid family is composed of camels, dromedaries, llamas, vicu ⁇ as, guanacos and alpacas.
- the antigen-binding fragment of an HCAb contains a single variable HHV domain consisting of 3 hypervariable regions. When isolated, the HHV domain is also known as a nanoantibody.
- Target-specific nanoantibodies derived from camelid HCAb are usually obtained rapidly after immunization with the most adjuvant target protein. Analysis of the structure of the nanoantibody reveals how hypervariable regions project in loops outside the structure of the nucleus.
- nanoantibodies are the best tools available today for affinity-based diagnostics and therapies.
- nanoantibodies Purification of nanoantibodies is simple compared to any other source of antibodies. They are often expressed attached to an affinity label, such as 6 ⁇ histidine labels, to allow affinity purification. Enrichment often sets in the bacterial periplasm where the oxidizing environment allows for the formation of suitable disulfide bonds. Several milligrams of a liter of culture can be isolated and recombinant isolated nanoantibodies can be further isolated using standard biochemical techniques.
- affinity label such as 6 ⁇ histidine labels
- Nanoantibodies are small, compact polypeptides and are often expressed in the periplasm of bacteria. They are very stable at high temperatures, starting at 6° C. compared to human VH, and are also resistant to denaturing chemical agents.
- molecular engineering of the nanoantibody structure has shown that stability increases when a cysteine is introduced at positions 54 and 78 to form an additional disulfide bond.
- the resulting superstable nanoantibody is also more resistant to proteases such as pepsin or chymotrypsin.
- Nanoantibodies can be used as therapeutic bullets against tumors, pathogens and chronic diseases, however, as foreign proteins, they could trigger an immune response on their own. Fortunately, the small size, rapid blood clearance and high homology with the human variable region of the VH heavy chain make them immunogenically small. Only some amino acids differ between nanoantibodies and human OAB, replacing these camelid amino acids with human amino acids has been used to humanize camelid nanoantibodies and make them even safer for therapies.
- Nanoantibodies are strict monomers, their affinity for substrates depends on the projection of the three hypervariable loops. Consequently, nanoantibodies tend to interact with cavities of the spatial structure of polypeptides, but not efficiently with peptides. For example, several identified nanoantibodies directly block active enzyme sites. The FC5 nanoantibody can even cross the blood-brain barrier via transcytosis and form partially bispecific antibodies used for therapeutic approaches. 52.53. Finally, molecular accessibility impacts access to macromolecular complexes.
- Nanoantibodies have been used for the purification by affinity of proteins in a specific way and even for the detection of post-translational modifications. However, the number of nanoantibodies available is very limited and many more are needed. Nanoantibodies can be used for various experimental environments such as ELISA, immunoprecipitation, CHIP-seq, immunostaining, to induce degradation of specific proteins by recruiting degradation machinery and blocking and activating cellular pathways.
- a nanoantibody obtained from alpacas specifically recognizes the green fluorescence protein, known as the GFP trap system, became the first-line tool for interaction and proteomics studies based on its extraordinary affinity and ability to bind to GFP fusion proteins. Today, it can even be used for GFP extraction from endogenously labeled proteins in combination with CRISPR/Cas9. GFP nanoantibody can also be coupled to fluorescent dyes to detect GFP by microscopy approaches when GFP levels are very low.
- nanoantibodies When a nanoantibody binds to a three-dimensional structure, some properties of the target protein change.
- One of the common features is that nanoantibodies limit the conformational changes of the target protein by promoting a unique conformation step. Surprisingly, these phenomena positively impact the possibilities of crystallization, therefore, nanoantibodies have been used as helpers to facilitate protein crystallization.
- Nanoantibodies are a superior tool for diagnosis. Their unlimited in vitro production capacity makes nanoantibodies more reliable than conventional antibodies and independent of batch preparation or animal serum limitations. Nanoantibodies can be produced as a protein fused with informant peptides or proteins for staining or direct visualization, including affinity tags (Flag, HA, V 5 , and cMyc), fluorescent proteins (GFP, RFP, etc.), and enzymes for colorimetric measurements such as horseradish peroxidase (HRP).
- affinity tags Flag, HA, V 5 , and cMyc
- fluorescent proteins GFP, RFP, etc.
- enzymes for colorimetric measurements such as horseradish peroxidase (HRP).
- ELISA assays can be improved by the use of nanoantibodies for specific immobilization or detection by the use of a specific nanoantibody coupled to horseradish peroxidase (HRP).
- Nanoantibodies meet most of the requirements of an ideal probe for successful molecular imaging.
- imaging techniques such as SPECT, PET, optical imaging and ultrasound have been successfully employed for molecular imaging by the use of in vivo nanoantibodies.
- SPECT specific targeted nanoantibodies are coupled to an irradiation source y administered systemically.
- the nanoantibodies are then detected in a whole-body scanner.
- the PET strategy is similar to SPECT, but instead uses positron-emitting radionuclide-labeled nanoantibodies.
- These imaging technologies are used for various tumor diagnostic techniques in animal models: for example, an anti-EGFR nanoantibody can be used to detect human squamous cell carcinoma and human prostate carcinoma.
- nanoantibodies have been developed in the context of different experimental therapeutic applications against different viruses: HIV, hepatitis B virus, influenza virus, respiratory syncytial virus, rabies virus, foot-and-mouth disease virus, poliovirus, rotavirus and PERV.
- nanoantibodies can neutralize HIV infection; cell-to-cell spread has been inhibited by the use of HIV isolated from patients. Due to the low immunoreactivity of nanoantibodies, they can be injected into patients with very few or no side effects.
- nanoantibodies can be linked to produce bivalent, multivalent, and/or multispecific nanoantibodies, or combined with other nanoantibodies or circulating proteins such as albumin to increase their turnover and therapeutic effectiveness.
- the rabies virus causes a lethal brain infection in people. Shortly after exposure, rabies prophylaxis with immunoglobulins and plasma-derived vaccines is administered. Often, this occurs directly after the attack of an animal that might be infected. Anti-rabies nanoantibodies can significantly prolong survival or even completely cure the disease in animal models.
- the respiratory syncytial virus, RSV is one of the leading causes of hospitalization in children, each year more than 1.9 million children under 1 year of age are infected and there are more than 0.3 million children under 5 years of age hospitalized. Current RSV therapy is not available. However, trivalent nanoantibody-based therapy is in phase II clinical trials.
- the absolute novelty of the RSV therapy developed by Ablynx, ALX-0171, is the direct neutralization of the virus in the lung of infected experimental animals.
- the nanoantibody is administered by nebulization and reduces the virus titer by 10,000 times. Nanoantibodies are also used for cancer immunotherapies.
- FIG. 1 Schematic representation of the protocol for HHV isolation using density gradient separation: the bacterial presentation library (I) expressing HHV on the surface of bacteria is briefly incubated (II) with conventional sepharosase beads coated with the antigen of interest. Immediately after depositing the mixture in a conical Ficoll density gradient (III) tube and centrifuging at 200 g for 1 min, the beads pass through the sequential selection of the density gradient to the bottom of the tube with the bacteria expressing specific HHV, while the unbound bacteria remain on the gradient surface. Next, the beads are resuspended and (IV) the incubating bacterial clones are isolated in agar plate.
- FIG. 2 Immunodetection of Spike-SARS-CoV2 in a nitrocellulose membrane with a pore size of 0.2 ⁇ m with the HHV of the invention as primary antibody, followed by mouse anti-Myc and goat anti-mouse IgG coupled to HRP. It includes photograph of each reaction for different nanoantibody selected with the method of the invention, as well as qualitative assessment (+, ++, +++)
- FIG. 3 Dot Blot against recombinant and synthetic polyubiquitin chains, by the use of Nb No. 34, mouse anti-myc and HRP-coupled anti-mouse.
- Nb No. 34 was expressed in the plasmid pNae2 (fused with intimin) with labels 6xHis and Myc.
- FIG. 4 Western Blot against recombinant and synthetic polyubiquitin chains, by the use of Nb No. 34, mouse anti-myc and mouse anti-HRP.
- Nb No. 34 was expressed in BL21 cells by the use of pNae2 (without intimin) with the Nb coding sequence between 6xHis and Myc.
- the invention allows for obtaining nanoantibodies quickly and easily, against any type of antigen, such as viruses, bacteria or microorganisms usually proteins or molecules, among others. But due to its speed, the method of this invention is very efficient for the generation of nanoantibodies against pathogens of emerging diseases, such as COVID.
- the invention relates to a method of separation of nanoantibodies (HHV) against a specific antigen from a nanoantibody expression library, wherein the method comprises the following steps:
- beads used are sepharose, cellulose, latex, agarose or nickel and can be modified to bind proteins, and have a density greater than the medium used in (c). These beads bind to the antigen of interest in a stable manner in a time of between 2 to 12 hours and then the sites that have not reacted with the antigen are blocked, by any means available in the technique.
- the bond between the beads and the antigen can be non-covalent covalent.
- this inert medium of stage (c) is preferably chosen between Ficol, percol or sucrose.
- the protein expression inducer is IPTG at a concentration between 20 to 100 ⁇ M.
- the microorganisms of the expression library are incubated with the beads attached to the antigen for between 20 to 60 minutes at room temperature.
- step (d) the beads are washed with PBS and seeded on agar plates with culture medium in order to obtain isolated colonies. Where each colony corresponds to a microorganism that expresses an HHV capable of binding to the antigen of interest.
- a purified antigen which can be obtained with a system of expression of baculovirus, bacteria, yeast or directly from its natural source.
- an animal producing nanoantibodies such as an alpaca or llama, is immunized between one-to four times with 50 to 500 ⁇ g of the antigen.
- the immune response of alpaca serum against the antigen after immunization can be observed rapidly and qualitatively by means of Dot Blot analysis, by immobilization of the epitope to a nitrocellulose membrane and by the use of alpaca serum as a source of primary antibodies; or analytically and comparatively by means of ELISA by the use of the complete antigen that is immobilized in the ELISA plate and the alpaca serum as a source of primary antibodies.
- a bacterial presentation library of individual nanoantibody clones is quickly built.
- the inventors created a method using beads made of polymers such as conventional sepharose or agarose which, in a density gradient, such as one obtained by the Ficoll reagent have shown that the density of the chosen beads was suitable for precipitating at the bottom of a 15 ml tube. At the same time, the inventors showed that, when performing the same test with free bacteria, the bacteria remained in the upper fraction. Revealing the possibility of separating free bacteria from those that express HHV and bind beads with the antigen, in a density gradient.
- a bacterial presentation system is usually used, where each bacterium expresses a single type of nanoantibody in its outer bacterial membrane after IPTG induction. Therefore, the inventors obtained sefarose beads coated with the antigen of interest to bind to individual bacteria expressing specific nanoantibodies on their surface against said antigen. Thus, bacteria expressing an HHV or nanoantibody that binds to the antigen sink to the bottom of the density gradient, while unbound bacteria would remain in the upper fraction ( FIG. 1 ).
- Example 1 The Simple Density Gradient Method of the Invention and its use to Obtain Nanoantibodies against the Spike Protein of SARS-CoV-2
- the alpaca immunization process followed the protocol “Animal use in research” generated by the Bioethics Committee of the Universidad Austral de Chile.
- One day before immunization 5 ml of blood was collected for preimmune serum testing.
- 100 ⁇ g of full-length SARS-CoV2 spike protein (SINOBiological) was used.
- the cold lyophilized protein was dissolved in 2 ml of adjuvant (veterinary vaccine adjuvant, GERBU FAMA) diluted 1:1 in sterile water and injected subcutaneously into a male alpaca ( Vicugna pacos ). A total volume of 4 ml was injected into four different sites of the alpaca.
- adjuvant veterinary vaccine adjuvant
- RNA extraction and cDNA production were carried out using the commercial RNeasy Mini (Qiagen) kit and the QuantiTect Reverse Transcription Kit (Qiagen), respectively.
- This fragment was used as a template in a second PCR reaction with oligonucleotides VHH-Sfi2 (5′-GTC CTC GCA ACT GCG GCC CAG CCGGCC ATG GCT CAG GTG CAG CTG GTG GA-3′) and VHH-Nott (5′-GGA CTA GTG CGG CCG CTG AGG AGA CGG TGA CCT GGG T-3′) to finally obtain the amplified fragments of ⁇ 0.4 kb, corresponding to VHH domains.
- VHH-Sfi2 5′-GTC CTC GCA ACT GCG GCC CAG CCGGCC ATG GCT CAG GTG CAG CTG GTG GA-3′
- VHH-Nott 5′-GGA CTA GTG CGG CCG CTG AGG AGA CGG TGA CCT GGG T-3′
- the amplified HHV fragments were digested with Sfi I and Notl (Thermo Scientific) restriction enzymes and bound at the same sites of the purified pNeae2 vector (Salema et al., 2016).
- the ligations were subjected to electroporation in cells of E. coli DH10B-T1 R achieving a library size of 2.3 ⁇ 10 6 individual clones, as determined by seeding on LB-Cloramphenicol agar plates with glucose at 2% w/v incubated at 30° C. Less than 0.7% of vectors re-linked from a control ligation carried out in parallel without the DNA insert was estimated.
- the transformed bacteria were scraped off the plates and stored at ⁇ 80 degrees in LB broth with 30% glycerol.
- the visible bead sediment contains bacteria that express an HHV that binds to antigens, in this case Sars-CoV2 Spike. This sediment was resuspended in 4 ml of PBS 1X and rotated for 5 min at room temperature. This step was repeated six times, in order to eliminate any bacteria not attached to the beads.
- nanoantibodies of the invention bind to the Spike protein
- an immunoblot was made for the 22 nanoantibodies, which faced Spike-GFP expressed in natural viral conditions in human cells ( FIG. 2 ).
- Mature and active ubiquitin is a small globular protein of 76 amino acids ( ⁇ 8 KDa) [107].
- Covalent modification of proteins by ubiquitin is defined as the formation of an isopeptide bond between the E-amino group of a lysine in the target protein and the C-terminal glycine (G 7 6) of ubiquitin.
- Ubiquitination occurs in different ways that regulate biological processes. It changes the specific properties of the target proteins that depend on i) the target itself and ii) the way ubiquitin binds.
- Ubiquitination of proteins with a single ubiquitin molecule has been described as regulating biological processes such as endocytosis, trafficking, and gene expression regulation.
- VHH against ubiquitin were developed.
- Example 2 The Simple Density Gradient Method of the Invention and its use to Obtain Nanoantibodies Against Ubiquitin
- the inventors obtained the various chains of polyubiquitins (K6, K11, K27, K29, K33, K48 and K63).
- An alpaca named Nick was immunized four times with 100 ⁇ g of the K48 polyubiquitin chain.
- a significant increase in IgG antibodies was observed in alpaca serum qualitatively rapidly by Dot Blot analysis, by immobilization of the epitope in a nitrocellulose membrane and by the use of alpaca serum as a source of primary antibodies. Therefore, the inventors quickly built a bacterial presentation library consisting of 1 ⁇ 10 6 clones of individual nanoantibodies with 1.2% vector religation.
- the alpaca immunization process followed the protocol “Animal use in research” generated by the Bioethics Committee of the Universidad Austral de Chile.
- One day before immunization 5 ml of blood was collected for preimmune serum testing.
- 100 ⁇ g of polyubiquitin k 48 chain was used for immunization (day 1 ).
- the cold lyophilized protein was dissolved in 2 ml of adjuvant (veterinary vaccine adjuvant, GERBU FAMA) diluted 1:1 in sterile water and injected subcutaneously into a male alpaca ( Vicugna pacos ).
- a total volume of 4 ml was injected into four different sites of the alpaca.
- a 5 ml blood sample was collected seven days after the first immunization.
- the alpaca was immunized again with 100 ⁇ g of the polyubiquitin k48 chain and so on for two more immunizations, until a day after the fourth immunization a 120 ml sample of blood was collected from the jugular vein in tubes containing 3.8% sodium citrate as an anticoagulant. And a library was generated in the same way as indicated for example 1.
- the inventors applied the method of the invention for the selection of nanoantibodies based on a simple density gradient.
- the preinoculum was sedimented and resuspended in LB medium with 25 ⁇ g mL-1 chloramphenicol and then diluted to 0.02 OD 600 nm in 100 ml of fresh LB medium with 25 ⁇ g mL-1 chloramphenicol without glucose, incubated at 37° C. with 200 rpm stirring to a OD 600 nm of 0.45 to 0.6.
- IPTG was added at a final concentration of 50 ⁇ M to induce protein expression for 3 hours at 30° C. and 200 rpm.
- the OD 600 nm absorbance of the library and control bacteria cultures was measured. 50 mL of both cultures were washed three times with 10 mL of filtered PBS 1C.
- the visible bead sediment contains bacteria that express an HHV that binds to antigens, in this case ubiquitin.
- This sediment was resuspended in 4 ml of PBS1X and rotated for 5 min at room temperature. This step was repeated six times, in order to eliminate any bacteria not attached to the beads.
- each colony obtained corresponds to a bacterium containing a nanoantibody or HHV that binds specifically to the antigen of interest
- the bacterial presentation system expresses nanoantibodies on the surface of bacteria fused with an intein protein and a myc tag. Buffer conditions were optimized to extract nanoantibody-intein fusion from the bacterial membrane and bacterial extract was used directly to confirm binding to polyubiquitin chains by dot blot. After selection of nanoantibodies using our simple density gradient protocol, 100 colonies were used to inoculate liquid LB medium and additionally induced for the expression of intein nanoantibodies. The cells were lysed under optimized conditions and the extract was used as a source of nanoantibodies as primary antibodies for the selection of antibodies that bind effectively by dot blot of the various chains of polyubiquitins immobilized in a nitrocellulose membrane.
- Nb No. 34 capable of recognizing all the ubiquitin chains tested by Dot Blot ( FIG. 3 ) and also by Western Blot ( FIG. 4 ). This was expressed in the plasmid pNae2 (fused with intimin) with 6xHis and Myc tags and then purified by nickel affinity chromatography. To perform the western blot, the different chains of polyubiquitins were separated electrophoretically in a 12% polyacrylamide gel and then transferred by electrotransfer to a nitrocellulose membrane which was incubated with the extract of Nb. No. 34 and successively with anti-myc antibody and anti-mouse antibody coupled to HRP.
- the invention proved useful for quickly and efficiently selecting nanoantibodies that bind specifically to an antigen of interest.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/998,753 US20230324403A1 (en) | 2020-05-15 | 2021-05-14 | One-step fast gradient method for nanoantibody generation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063025534P | 2020-05-15 | 2020-05-15 | |
US17/998,753 US20230324403A1 (en) | 2020-05-15 | 2021-05-14 | One-step fast gradient method for nanoantibody generation |
PCT/CL2021/050039 WO2021226728A1 (fr) | 2020-05-15 | 2021-05-14 | Méthode de gradient rapide à un seul passage pour la production d'anticorps |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230324403A1 true US20230324403A1 (en) | 2023-10-12 |
Family
ID=78525891
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/998,753 Pending US20230324403A1 (en) | 2020-05-15 | 2021-05-14 | One-step fast gradient method for nanoantibody generation |
US18/055,589 Pending US20240067705A1 (en) | 2020-05-15 | 2022-11-15 | Single domain vhh antibodies against sars-cov-2 virus |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/055,589 Pending US20240067705A1 (en) | 2020-05-15 | 2022-11-15 | Single domain vhh antibodies against sars-cov-2 virus |
Country Status (9)
Country | Link |
---|---|
US (2) | US20230324403A1 (fr) |
EP (2) | EP4151784A4 (fr) |
KR (1) | KR20230065931A (fr) |
CN (2) | CN115867350A (fr) |
AR (1) | AR122104A1 (fr) |
BR (1) | BR112022023168A2 (fr) |
CA (1) | CA3178663A1 (fr) |
CL (2) | CL2022003165A1 (fr) |
WO (3) | WO2021229540A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115043934B (zh) * | 2022-03-31 | 2023-06-27 | 深圳市人民医院 | 靶向新冠病毒的纳米抗体及其制备方法和应用 |
CN114478758B (zh) * | 2022-04-01 | 2022-06-21 | 深圳市人民医院 | 靶向SARS-CoV-2的纳米抗体及制备方法和应用 |
CN116375852B (zh) * | 2023-03-10 | 2024-02-02 | 华南农业大学 | 重组荧光纳米抗体及其在制备狂犬病病毒检测试剂中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1558645B1 (fr) * | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Anticorps a domaine unique stabilises dans une composition pharmaceutique pour inhalation |
US20130332133A1 (en) * | 2006-05-11 | 2013-12-12 | Ramot At Tel Aviv University Ltd. | Classification of Protein Sequences and Uses of Classified Proteins |
CA2677383A1 (fr) * | 2007-02-09 | 2008-08-21 | Medimmune, Llc | Banque d'anticorps presentes sur la membrane plasmique de cellules de levure |
WO2010033913A1 (fr) * | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Anticorps, analogues et leurs utilisations |
US20110214205A1 (en) * | 2010-02-26 | 2011-09-01 | Monsanto Technology Llc. | Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits |
-
2021
- 2021-05-14 CN CN202180048558.5A patent/CN115867350A/zh active Pending
- 2021-05-14 EP EP21804101.0A patent/EP4151784A4/fr active Pending
- 2021-05-14 CA CA3178663A patent/CA3178663A1/fr active Pending
- 2021-05-14 AR ARP210101339A patent/AR122104A1/es unknown
- 2021-05-14 CN CN202180048506.8A patent/CN115917061A/zh active Pending
- 2021-05-14 US US17/998,753 patent/US20230324403A1/en active Pending
- 2021-05-14 WO PCT/IB2021/054171 patent/WO2021229540A2/fr active Application Filing
- 2021-05-14 WO PCT/CL2021/050040 patent/WO2021226729A1/fr active Application Filing
- 2021-05-14 KR KR1020227044002A patent/KR20230065931A/ko active Search and Examination
- 2021-05-14 BR BR112022023168A patent/BR112022023168A2/pt unknown
- 2021-05-14 EP EP21804589.6A patent/EP4149626A4/fr active Pending
- 2021-05-14 WO PCT/CL2021/050039 patent/WO2021226728A1/fr active Application Filing
-
2022
- 2022-11-14 CL CL2022003165A patent/CL2022003165A1/es unknown
- 2022-11-14 CL CL2022003173A patent/CL2022003173A1/es unknown
- 2022-11-15 US US18/055,589 patent/US20240067705A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112022023168A2 (pt) | 2023-02-07 |
EP4149626A2 (fr) | 2023-03-22 |
AR122104A1 (es) | 2022-08-10 |
WO2021229540A2 (fr) | 2021-11-18 |
CN115867350A (zh) | 2023-03-28 |
US20240067705A1 (en) | 2024-02-29 |
EP4149626A4 (fr) | 2024-07-24 |
EP4151784A1 (fr) | 2023-03-22 |
WO2021226729A1 (fr) | 2021-11-18 |
WO2021226728A1 (fr) | 2021-11-18 |
CN115917061A (zh) | 2023-04-04 |
WO2021229540A3 (fr) | 2021-12-23 |
CL2022003165A1 (es) | 2023-03-24 |
CA3178663A1 (fr) | 2021-11-18 |
KR20230065931A (ko) | 2023-05-12 |
CL2022003173A1 (es) | 2023-07-07 |
EP4151784A4 (fr) | 2024-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230324403A1 (en) | One-step fast gradient method for nanoantibody generation | |
US11866785B2 (en) | Tumor specific antibodies and T-cell receptors and methods of identifying the same | |
JP5941615B2 (ja) | ヒトcxcl1タンパク質の免疫学的測定方法 | |
KR102671155B1 (ko) | Ns1 단백질의 결합 단백질 | |
US20210301000A1 (en) | NS1-Binding Protein and Uses Thereof | |
CN106866820B (zh) | 一种用于捕获肿瘤细胞的抗人角蛋白18的单克隆抗体及其应用 | |
CN106854244B (zh) | 一种针对her3的纳米抗体及其临床应用 | |
JP2022512630A (ja) | 抗ヒト心筋型トロポニンi抗体及びその応用 | |
JPWO2016143226A1 (ja) | 反応場を制限したプロテアーゼ分解反応による抗体からペプチド断片を得る方法 | |
WO2013015367A1 (fr) | Anticorps pour la détection d'un marqueur du cancer épithélial de l'ovaire et méthode pour le diagnostic du cancer épithélial de l'ovaire | |
JP6744670B2 (ja) | タグ付抗体 | |
JP5770092B2 (ja) | ヒトhig1ポリペプチドに対するモノクローナル抗体 | |
EP2187216B1 (fr) | Nouveau marqueur de cancer du foie | |
CN117683128B (zh) | 一种全人源针对鼠疫菌的保护性单克隆抗体及其应用 | |
WO2022071581A1 (fr) | Peptide de liaison au sars-cov-2 | |
JP5849275B2 (ja) | 抗ヒスチジンタグ抗体 | |
WO2015137441A1 (fr) | Anticorps anti-protéine myristoylée ou fragment de liaison à l'antigène de celui-ci, trousse de détection d'une protéine myristoylée, médicament, gène et vecteur | |
JP5849254B2 (ja) | 上皮性卵巣癌マーカー検出用抗体及び上皮性卵巣癌判定方法 | |
US20240168026A1 (en) | Method and kit for assisting in determination of malignant pancreatic cystic tumor | |
WO2019230823A1 (fr) | Procédé d'obtention d'anticorps, procédé d'identification d'anticorps, procédé de production d'anticorps et anticorps | |
WO2024089627A1 (fr) | Anticorps à domaine unique -sdab/vhh dirigé contre la nucléoprotéine du virus sars-cov-2 | |
CN116554321A (zh) | 一种znf165特异性抗体 | |
CN118667000A (zh) | 抗hsa单克隆抗体及其应用 | |
KR100477898B1 (ko) | 인간 CacyBP/SIP에 대한 단일클론 항체 및 이를생산하는 융합세포주 | |
JP2012070648A (ja) | マウスhig1ポリペプチドに対するモノクローナル抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSIDAD AUSTRAL DE CHILE, CHILE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROJAS, ALEJANDRO;VALENZUELA, GUILLERMO;JARA, RONALD;AND OTHERS;SIGNING DATES FROM 20221110 TO 20221114;REEL/FRAME:061780/0153 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |